Question 1

What is the standard tesamorelin dose?

Accepted Answer

The FDA-approved dose is 2 mg daily via subcutaneous injection in the abdominal area. This dose was established through Phase 3 clinical trials in HIV-associated lipodystrophy and applies to both Egrifta and Egrifta SV formulations. Higher and lower doses were tested in dose-ranging studies; 2 mg provided the optimal balance of visceral fat reduction and tolerability.

Question 2

How long do you take tesamorelin?

Accepted Answer

The FDA Egrifta labeling recommends evaluating results at 26 weeks. If no meaningful reduction in visceral adipose tissue is achieved by 26 weeks, treatment should be discontinued. For responders, treatment continues as long as clinical benefit persists. Visceral fat tends to return on discontinuation, so long-term continuous use is the typical maintenance pattern.

Question 3

Where do I inject tesamorelin?

Accepted Answer

FDA labeling specifies subcutaneous injection in the abdominal area. Rotate sites within the abdomen to prevent lipohypertrophy and improve consistency of absorption. Avoid the area within 5 cm of the navel. The thigh and upper arm are not FDA-recommended sites for tesamorelin specifically; the trial data is based on abdominal administration.

Question 4

Should I take tesamorelin in the morning or at night?

Accepted Answer

FDA labeling does not specify timing relative to time of day or meals. Practical recommendations from clinical use: inject at a consistent time each day to maintain steady GH stimulation; morning dosing aligns with the body's natural cortisol and GH rhythms; avoid injection immediately after high-carbohydrate meals because elevated blood glucose can blunt GH release. Many users prefer bedtime to pair with the natural nocturnal GH surge.

Question 5

How do I reconstitute Egrifta SV?

Accepted Answer

Egrifta SV comes as a single-vial lyophilized powder. Reconstitute with 0.5 mL of the provided sterile water for injection (or 2.1 mL for the original Egrifta formulation, per its specific instructions). The reconstituted solution should be used immediately — do not store reconstituted solution. For research-grade tesamorelin in different vial sizes, use the peptide calculator for volumes.

Question 6

Do I need to monitor anything on tesamorelin?

Accepted Answer

Per FDA labeling: periodic IGF-1 levels (discontinue if persistently elevated above age-adjusted upper limit of normal), fasting glucose and HbA1c (tesamorelin can impair glucose tolerance), and visceral fat assessment at 26 weeks by CT or other imaging. Also monitor for hypersensitivity reactions during initial administrations.

Parameter	Detail
Dose	2 mg daily
Route	Subcutaneous injection
Site	Abdominal area, rotating injection sites
Timing	Once daily, at the same time each day
Assessment	Evaluate at 26 weeks; discontinue if no improvement in visceral fat

Tesamorelin: Dosage & Administration

FDA-Approved Dosing

Reconstitution

Monitoring Requirements

Timing Considerations

Frequently Asked Questions

Researching peptides? We did the hard part.

Peptides for Weight Loss

Peptides for Muscle Growth

Peptides for Healing

How to Reconstitute Peptides

How to Inject Peptides

Peptide Reconstitution Calculator